시장보고서

상품코드

1771662

미국의 첨단 창상 관리 OTC 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품별, 용도별, 유통 채널별, 부문별 예측(2025-2033년)

U.S. Advanced Wound Care OTC Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, And Segment Forecasts, 2025 - 2033

발행일: 2025년 06월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

미국의 첨단 창상 관리 OTC 시장 요약

미국의 첨단 창상 관리 OTC 시장 규모는 2024년에 27억 7,000만 달러로 평가되었고, 2033년에는 66억 1,000만 달러에 이를 것으로 예측되며, 2025-2033년 연평균 복합 성장률(CAGR)은 10.33%로 성장할 전망입니다. 성장을 견인하는 것은 수술 창상, 외상, 화상 등의 급성 창상 증가이며 효과적이고 신속한 창상 관리 솔루션이 필요합니다.

세계 교통사고, 스포츠 외상, 외과 수술 증가로 치유를 가속화하고 감염 위험을 줄이는 첨단 OTC 창상 관리 제품 수요가 급증하고 있습니다. 토탈 패밀리 케어 센터가 2025년 4월에 발표한 데이터에 의하면, 미국에서는 연간 약 1,100만 명이 급성 창상을 경험해, 약 30만 건이 병원 치료를 필요로 하고 있습니다. 또, 적절한 창상 케어의 실천에 관한 소비자 의식 고조 및 소매 약국이나 온라인 플랫폼을 통해서 고도의 드레싱재를 용이하게 입수할 수 있는 것이, 계속해 시장의 확대를 지지하고 있습니다.

미국에서는 당뇨병의 유병률이 높고, 증가 경향에 있는 것이 시장의 성장을 크게 뒷받침하고 있습니다. 당뇨병은 만성창상, 특히 당뇨병성 족궤양이 발병하는 중대한 위험인자로 감염병이나 절단 등 합병증을 예방하기 위해서는 시기적절하고 효과적인 창상관리가 필요합니다. 예를 들면, 미국 질병예방관리센터(CDC)의 보고에 의하면, 3,800만 명 이상의 미국인이 당뇨병을 앓고 있고(약 10명 중 1명), 그 중 약 90-95%가 제2형 당뇨병입니다.

경미한 창상을 관리하고 창상의 악화를 막을 수 있는 이용하기 쉬운 시판의 창상 관리 제품에 대한 수요가 높아지고 있습니다. 첨단 OTC 창상 관리 제품은 당뇨병 환자에게 집에서 창상을 치료하는 편리한 방법을 제공하여 잦은 진료의 필요성을 줄여줍니다. 이러한 당뇨병 환자들의 셀프케어에 대한 요구 증대가 미국의 첨단 창상 관리 OTC 산업의 확대를 뒷받침하고 있습니다.

시장 계통 전망
- 상위 시장 전망
- 보조 시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 시장 기회 분석
- 시장 과제 분석
미국의 첨단 창상 관리 OTC 시장 분석 툴
- 업계 분석-Porter's Five Forces 분석
- PESTEL 분석

제4장 미국의 첨단 창상 관리 OTC 시장 : 제품별 추정 및 동향 분석

부문 대시보드
미국의 첨단 창상 관리 OTC 시장 : 변동 분석
미국의 첨단 창상 관리 OTC 시장 : 제품별 규모 및 동향 분석(2021-2033년)
폼 드레싱
- 접착제
- 비점착 폼 드레싱
필름 드레싱
하이드로콜로이드
하이드로겔 드레싱
허니 드레싱
기름 같은 거즈
부직포술 후 드레싱
기타

제5장 미국의 첨단 창상 관리 OTC 시장 : 용도별 추정 및 동향 분석

부문 대시보드
미국의 첨단 창상 관리 OTC 시장 : 변동 분석
미국의 첨단 창상 관리 OTC 시장 : 용도별 규모 및 동향 분석(2021-2033년)
만성 창상
- 당뇨병성 발 궤양(1단계, 2단계, 3단계, 4단계, 심부 조직 손상 포함)
- 욕창
- 정맥성 다리 궤양
- 기타 만성 창상
급성 창상
- 외과적 창상 및 외상(피부 열상 포함)
- 화상

제6장 미국의 첨단 창상 관리 OTC 시장 : 유통 채널별 추정 및 동향 분석

부문 대시보드
미국의 첨단 창상 관리 OTC 시장 : 변동 분석
미국의 첨단 창상 관리 OTC 시장 : 유통 채널별 규모 및 동향 분석(2021-2033년)
소매 약국 및 약국
전자상거래, 온라인 약국 및 건강 관련 전자상거래
기타

제7장 경쟁 구도

시장 진출기업의 분류
주요 기업 프로파일
Company Share Analysis, 2024
- Smith+Nephew
- Solventum
- Molnlycke Health Care AB
- 3M
- Convatec Inc.
- Lavior
- Vomaris Innovations, Inc.
- B. Braun SE
- Coloplast Group
- PAUL HARTMANN AG
- Beiersdorf
- Dimora Medical
- Remedium Healthcare Products
- Sonoma Pharmaceuticals, Inc.
- Cardinal Health
- DeRoyal Industries, Inc.
- Medline Industries, LP
- Lavior

AJY

U.S. Advanced Wound Care OTC Market Summary

The U.S. advanced wound care OTC market size was estimated at USD 2.77 billion in 2024 and is projected to reach USD 6.61 billion by 2033, growing at a CAGR of 10.33% from 2025 to 2033. The growth is driven by the increasing prevalence of acute wounds, such as surgical wounds, traumatic injuries, and burns, which require effective and immediate wound management solutions.

Rising rates of road accidents, sports injuries, and surgical procedures globally have led to a surge in demand for advanced OTC wound care products that promote faster healing and reduce the risk of infection. According to the data published by the Total Family Care Center in April 2025, approximately 11 million individuals in the U.S. experience acute wounds annually, with around 300,000 cases requiring hospital care. In addition, the growing awareness among consumers regarding proper wound care practices and the ease of access to advanced dressings through retail pharmacies and online platforms continue to support market expansion.

The high and rising prevalence of diabetes in the U.S. significantly drives the growth of the market. Diabetes is a significant risk factor for the development of chronic wounds, particularly diabetic foot ulcers, which require timely and effective wound management to prevent complications such as infections and amputations. For instance, the Centers for Disease Control and Prevention (CDC) reports that more than 38 million Americans have diabetes (about 1 in 10), and about 90% to 95% of them have type 2 diabetes.

There is an increasing demand for accessible, over-the-counter wound care products that allow individuals to manage minor wounds and prevent them from worsening. Advanced OTC wound care solutions offer diabetic patients a convenient way to treat wounds at home, reducing the need for frequent clinical visits. This growing need for self-care solutions among the diabetic population is a key factor propelling the expansion of the U.S. advanced wound care OTC industry.

U.S. Advanced Wound Care OTC Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. advanced wound care OTC market report based on product, application, and distribution channel.

Product Outlook (Revenue, USD Million, 2021 - 2033)
Foam Dressings
- Adhesive
- Non-adhesive Foam Dressings
Film Dressings
Hydrocolloids
Hydrogel Dressings
Honey Dressings
Greasy Gauzes
Non-Woven Post Operative Dressings
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Chronic Wounds
- Diabetic Foot Ulcers
- Pressure Ulcers (Stage 1, Stage 2, Stage 3, Stage 4, and Deep Tissue Injury included)
- Venous Leg Ulcers
- Other Chronic Wounds
Acute Wounds
- Surgical & Traumatic Wounds (skin tears included)
- Burns
- 1st degree burns
- 2nd degree burns
- 3rd degree burns
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Retail Pharmacies / Drugstores
E-commerce/Online Pharmacies / Health E-tailers
Others

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Application
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. Advanced Wound Care OTC Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Increasing adoption of digital distribution platforms
  - 3.2.1.2. Rising burden of wounds
  - 3.2.1.3. Increasing approvals for advanced wound care OTC products
  - 3.2.1.4. Rising aging population in the U.S.
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Product recalls
- 3.2.3. Market Opportunities Analysis
  - 3.2.3.1. Shift from institutional settings to home care
  - 3.2.3.2. Increasing number of road accidents and injuries
  - 3.2.3.3. Expansion opportunity in post-surgical wound management
- 3.2.4. Market Challenge Analysis
3.3. U.S. Advanced Wound Care OTC Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Bargaining power of suppliers
  - 3.3.1.2. Bargaining power of buyers
  - 3.3.1.3. Threat of substitutes
  - 3.3.1.4. Threat of new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political & Legal Landscape
  - 3.3.2.2. Economic and Social Landscape
  - 3.3.2.3. Technological landscape

Chapter 4. U.S. Advanced Wound Care OTC Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. U.S. Advanced Wound Care OTC Market Movement Analysis
4.3. U.S. Advanced Wound Care OTC Market Size & Trend Analysis, by Product, 2021 - 2033 (USD Million)
4.4. Foam Dressings
- 4.4.1. Foam Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Adhesive
  - 4.4.2.1. Adhesive Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Non-adhesive Foam Dressings
  - 4.4.3.1. Non-adhesive Foam Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Film Dressings
- 4.5.1. Film Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Hydrocolloids
- 4.6.1. Hydrocolloids Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Hydrogel Dressings
- 4.7.1. Hydrogel Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Honey Dressings
- 4.8.1. Honey Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Greasy Gauzes
- 4.9.1. Greasy Gauzes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.10. Non-Woven Post Operative Dressings
- 4.10.1. Non-Woven Post Operative Dressings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.11. Others
- 4.11.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Advanced Wound Care OTC Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. U.S. Advanced Wound Care OTC Market Movement Analysis
5.3. U.S. Advanced Wound Care OTC Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Chronic Wounds
- 5.4.1. Chronic Wounds Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.2. Diabetic Foot Ulcers (Stage 1, Stage 2, Stage 3, Stage 4 and Deep Tissue Injury included)
  - 5.4.2.1. Diabetic Foot Ulcers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.3. Pressure Ulcers
  - 5.4.3.1. Pressure Ulcers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.4. Venous Leg Ulcers
  - 5.4.4.1. Venous Leg Ulcers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.5. Other Chronic Wounds
  - 5.4.5.1. Other Chronic Wounds Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Acute Wounds
- 5.5.1. Acute Wounds Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5.2. Surgical & Traumatic Wounds (skin tears included)
  - 5.5.2.1. Surgical & Traumatic Wounds (skin tears included) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5.3. Burns
  - 5.5.3.1. Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.5.3.2. 1st Degree Burns
    - 5.5.3.2.1. 1st Degree Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.5.3.3. 2nd Degree Burns
    - 5.5.3.3.1. 2nd Degree Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 5.5.3.4. 3rd Degree Burns
    - 5.5.3.4.1. 3rd Degree Burns Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Advanced Wound Care OTC Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. U.S. Advanced Wound Care OTC Market Movement Analysis
6.3. U.S. Advanced Wound Care OTC Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Retail Pharmacies / Drugstores
- 6.4.1. Retail Pharmacies / Drugstores Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. E-commerce/Online Pharmacies / Health E-tailers
- 6.5.1. E-commerce/Online Pharmacies / Health E-tailers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

7.1. Market Participant Categorization
7.2. Key Company Profiles
7.3. Company Share Analysis, 2024
- 7.3.1. Smith+Nephew
  - 7.3.1.1. Company Overview
  - 7.3.1.2. Financial Performance
  - 7.3.1.3. Product Benchmarking
  - 7.3.1.4. Strategic Initiatives
- 7.3.2. Solventum
  - 7.3.2.1. Company Overview
  - 7.3.2.2. Financial Performance
  - 7.3.2.3. Product Benchmarking
  - 7.3.2.4. Strategic Initiatives
- 7.3.3. Molnlycke Health Care AB
  - 7.3.3.1. Company Overview
  - 7.3.3.2. Financial Performance
  - 7.3.3.3. Product Benchmarking
  - 7.3.3.4. Strategic Initiatives
- 7.3.4. 3M
  - 7.3.4.1. Company Overview
  - 7.3.4.2. Financial Performance
  - 7.3.4.3. Product Benchmarking
  - 7.3.4.4. Strategic Initiatives
- 7.3.5. Convatec Inc.
  - 7.3.5.1. Company Overview
  - 7.3.5.2. Financial Performance
  - 7.3.5.3. Product Benchmarking
  - 7.3.5.4. Strategic Initiatives
- 7.3.6. Lavior
  - 7.3.6.1. Company Overview
  - 7.3.6.2. Financial Performance
  - 7.3.6.3. Product Benchmarking
  - 7.3.6.4. Strategic Initiatives
- 7.3.7. Vomaris Innovations, Inc.
  - 7.3.7.1. Company Overview
  - 7.3.7.2. Financial Performance
  - 7.3.7.3. Product Benchmarking
  - 7.3.7.4. Strategic Initiatives
- 7.3.8. B. Braun SE
  - 7.3.8.1. Company Overview
  - 7.3.8.2. Financial Performance
  - 7.3.8.3. Product Benchmarking
  - 7.3.8.4. Strategic Initiatives
- 7.3.9. Coloplast Group
  - 7.3.9.1. Company Overview
  - 7.3.9.2. Financial Performance
  - 7.3.9.3. Product Benchmarking
  - 7.3.9.4. Strategic Initiatives
- 7.3.10. PAUL HARTMANN AG
  - 7.3.10.1. Company Overview
  - 7.3.10.2. Financial Performance
  - 7.3.10.3. Product Benchmarking
  - 7.3.10.4. Strategic Initiatives
- 7.3.11. Beiersdorf
  - 7.3.11.1. Company Overview
  - 7.3.11.2. Financial Performance
  - 7.3.11.3. Product Benchmarking
  - 7.3.11.4. Strategic Initiatives
- 7.3.12. Dimora Medical
  - 7.3.12.1. Company Overview
  - 7.3.12.2. Financial Performance
  - 7.3.12.3. Product Benchmarking
  - 7.3.12.4. Strategic Initiatives
- 7.3.13. Remedium Healthcare Products
  - 7.3.13.1. Company Overview
  - 7.3.13.2. Financial Performance
  - 7.3.13.3. Product Benchmarking
  - 7.3.13.4. Strategic Initiatives
- 7.3.14. Sonoma Pharmaceuticals, Inc.
  - 7.3.14.1. Company Overview
  - 7.3.14.2. Financial Performance
  - 7.3.14.3. Product Benchmarking
  - 7.3.14.4. Strategic Initiatives
- 7.3.15. Cardinal Health
  - 7.3.15.1. Company Overview
  - 7.3.15.2. Financial Performance
  - 7.3.15.3. Product Benchmarking
  - 7.3.15.4. Strategic Initiatives
- 7.3.16. DeRoyal Industries, Inc.
  - 7.3.16.1. Company Overview
  - 7.3.16.2. Financial Performance
  - 7.3.16.3. Product Benchmarking
  - 7.3.16.4. Strategic Initiatives
- 7.3.17. Medline Industries, LP
  - 7.3.17.1. Company Overview
  - 7.3.17.2. Financial Performance
  - 7.3.17.3. Product Benchmarking
  - 7.3.17.4. Strategic Initiatives
- 7.3.18. Lavior
  - 7.3.18.1. Company Overview
  - 7.3.18.2. Financial Performance
  - 7.3.18.3. Product Benchmarking
  - 7.3.18.4. Strategic Initiatives